Atlas Trials

Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma

Clinical trial NCT03190213 · TERMINATED

Trial details

NCT number
NCT03190213
Sponsor
University of Utah
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2017-12-04
Primary completion
2018-12-13
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.